HomePatient InformationHealthcare Professional
  NeutroSpec™ [Technetium (99m Tc) fanolesomab]
helps assure accurate patient diagnosis.

NeutroSpec is an in vivo imaging agent that radiolabels white blood cells and is to be used for rapid scintigraphic imaging of patients 5 years of age or older with signs of equivocal appendicitis. NeutroSpec imaging agent has a uniquely high affinity for binding to white blood cells which gather at the site of the infected appendix. The “labeled” white blood cells allow the infection to be detected with a gamma camera. NeutroSpec imaging agent is injected in vivo; no blood handling or in vitro cell labeling is required.

A NeutroSpec image allows a physician to more rapidly obtain necessary diagnostic information to support patient management decisions. 1

Uniquely Attractive

Binds with a uniquely high affinity to white blood cells. NeutroSpec monoclonal antibody “binds avidly to surface CD 15 antigens that are expressed on human neutrophils in large numbers.” 1


In most cases, diagnosis can be made within one hour after injection.

“In patients with appendicitis and positive scans more than 50 percent of the images were positive at 4 minutes, and all were positive by 1 hour.” 2


An in vivo imaging agent — requires no blood handling.

“As a result of the in vivo systemic administration of radiolabeled... [NeutroSpec], radioactivity becomes concentrated in areas of infection or inflammation; thus, the need to withdraw blood from a patient to label WBC’s ex vivo is eliminated and the time required to perform the test is reduced significantly.” 1


Quick and easy prep kit.

After addition of 20-40 mCi of Tc 99m generator eluant, a 30 minute incubation at 37ºC, and addition of Cenolate™, NeutroSpec imaging agent is ready for patient injection. A NeutroSpec imaging agent injection is administered in a single dose with 10-20 mCi of Tc 99m, corresponding to 75-125 µg of fanolesomab.

Indicated For Appendicitis

Indicated for the diagnosis of appendicitis in patients, 5 years or older, with equivocal signs and symptoms.

1 Rypins E, Kipper S, Weiland F, et al, (99m Tc) Anti-Cd 15 monoclonal antibody imaging improves diagnostic accuracy and clinical management in patients with equivocal presentation of appendicitis. Annals of Surgery, February 2002; Vol. 235, No. 2: 232-239.
2 Rypins E, Kipper S, Scintigraphic Determination of Equivocal Appendicitis. The American Surgeon, September 2000; Vol. 66, No. 9: 891-895.
Cenolate™ is a trademark of Hospira, Inc.

NeutroSpec™ [Technetium (99m Tc) fanolesomab] contains both murine antibodies and sodium hydrosulfite, each of which has been known to induce allergic reactions, including anaphylaxis. The most frequently observed adverse events seen in clinical studies were flushing and dyspnea.

See Prescribing Information